ACT Genomics

9:45 AM - 10:00 AM, Wednesday, October 23, 2019 ・ 2nd Floor
ACT Genomics is a leading molecular information company, integrating clinical grade next-generation sequencing and proprietary bioinformatics algorithm to guide cancer treatment and accelerate drug development. Company now has NGS labs in Taiwan, Hong Kong and Japan. Our Taiwan lab is accredited by CAP to provide NGS services for clinical cancer genetic testing including bio-informatics. ACT Genomics has the complete product portfolio that covers different stages of cancer management, including cancer prevention, treatment selection, and disease monitoring. We are developing an AI engine to extract valuable information from our cancer genome database enriched with Asian high prevalent tumor to facilitate the decision-making process and to identify novel drug target. Besides next generation sequencing platform, we are dedicated in developing chip-based molecular assays to identify actionable targets and biomarkers that are more feasible and affordable in clinical setting.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Taiwan
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
ACTOnco®
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CSO and Co-Founder
ACT Genomics Co., Ltd.